HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and year ended March 31, 2025....新加坡--(BUSINESS WIRE)--(美國商業資訊)-- Ant International（中文名：螞蟻國際）與首屈一指的英國銀行Barclays締結協議，將合作提高企業全球金融管理的效率與彈性。這份合作關係將結合雙邊的創新解決方案（包括Ant的專屬時間序列轉換器 (TST) 人工智慧外匯模型在內），協助企業降低外匯相關成本，對抗全球波動帶來的風險。 Ant International已在合作的初步階段與Barclays順利完成該集團內的第一批外匯交易。 Ant International的時間序列轉換器模型是一個以轉換器為基礎架構的大數據模型，擁有近20億個參數。這款時間序列轉換器模型整合最新的時間序列預測演算法，可預測隨時間變化的模式。Ant還引入新的預訓練和監督式微調 (SFT) 框架來訓練模型，改善其隨時間變動進行預測的能力。 時間序列轉換器模型目前以每小時、每日、每星期為週期預測該公司的現金流以及外匯風險，準確性在90%以上。這可以提高預測交易量的準確性，並減少被銀行收取不必要的對沖和風險溢價成本，進而降低對沖成本和外匯總成本。 Barclays將時間序列轉換器模型...新加坡--(BUSINESS WIRE)--(美国商业资讯)-- Ant International 与英国知名银行 Barclays 达成合作，共同提升企业在全球资金管理方面的效率与韧性。双方将通过创新技术方案，包括 Ant 专有的 Time-Series Transformer（TST）AI FX Model，帮助企业应对全球市场波动，降低外汇相关成本与风险。 合作初期，Ant International 已成功完成与 Barclays 的首批集团内部外汇交易。 Ant International 的 TST Model 是一个基于 transformer 架构的大数据模型，拥有近20亿参数。通过整合最新的时间序列预测算法，TST 模型能够识别和预测趋势变化。Ant 还创建了新的预训练和监督微调 (SFT) 框架，用于训练模型并不断提升其预测能力。 目前，TST 模型可按小时、每日和每周预测公司现金流与外汇敞口，准确率超过 90%。这使得交易量预测更加准确，减少不必要的对冲操作和银行风险溢价成本，从而降低对冲成本和整体外汇成本。 Barclays 将 TST 模型整合至其外汇对冲平...SINGAPUR--(BUSINESS WIRE)--Ant International ist eine Partnerschaft mit der führenden britischen Bank Barclays eingegangen, um die Effizienz und Widerstandsfähigkeit des globalen Treasury-Managements für Unternehmen zu verbessern. Im Rahmen der Partnerschaft werden beide Seiten innovative Lösungen kombinieren, darunter das proprietäre Time-Series Transformer (TST) AI FX-Modell von Ant, um Unternehmen dabei zu unterstützen, ihre FX-bezogenen Kosten und Risiken angesichts globaler Volatilitäten z...HOUSTON--(BUSINESS WIRE)--Phillips 66 today provided investors with important information to make fully informed voting decisions at the Phillips 66 Annual Meeting on May 21....SINGAPOUR--(BUSINESS WIRE)--Ant International a conclu un partenariat stratégique avec la grande banque britannique Barclays afin d'aider les entreprises à optimiser et à renforcer la gestion de leur trésorerie internationale. Dans ce cadre, les deux entités uniront leurs forces pour mettre en commun des solutions technologiques innovantes, dont le modèle exclusif d’intelligence artificielle FX Time-Series Transformer (TST) développé par Ant, afin d'aider les entreprises à réduire leurs coûts e...SINGAPORE--(BUSINESS WIRE)--Ant International sluit een partnerschap met Barclays, de vooraanstaande bank van de UK, om efficiëntie en veerkracht in globaal kasmiddelenbeheer voor bedrijven te bevorderen. In het kader van dit partnerschap zullen beide partijen innovatieve oplossingen combineren, waaronder het eigen Time-Series Transformer (TST) AI FX Model van Ant, om bedrijven te helpen kosten en risico's in verband met wisselkoersen ten overstaan van wereldwijde volatiliteit te beperken. In d...NEW YORK--(BUSINESS WIRE)--Labaton Keller Sucharow LLP (“Labaton”) announces the reopening of the lead plaintiff appointment process in a class action lawsuit against Rock Holdings, Inc. (“RHI”). The action, which is captioned Construction Laborers Pension Trust for Southern California v. Rocket Companies, Inc., No. 21-cv-11528-TLL-APP (E.D. Mich.) asserts claims under Section 10(b) and Section 20A of the Securities Exchange Act of 1934, on behalf of all persons who purchased Rocket Companies,...ISTANBUL--(BUSINESS WIRE)--Turkcell Iletisim Hizmetleri A.S. (NYSE:TKC) (BIST:TCELL): Please note that all financial data is consolidated and comprises that of Turkcell Iletisim Hizmetleri A.S. (the “Company” or “Turkcell”) and its subsidiaries and associates (together referred to as the “Group”) unless otherwise stated. As of Q1 2025, we have revised our revenue segmentation. The figures are presented according to this new structure. Please refer to page 4 and the Excel file available on the T...PORT ARTHUR, Texas--(BUSINESS WIRE)--Veolia has published the waste management industry’s most comprehensive testing to date on the incineration of PFAS compounds. The tests demonstrated that high temperature incineration is a proven and reliable disposal solution for high concentrations of targeted PFAS, destroying greater than 99% of targeted substances, including up to 99.9999% of PFOS and PFHxS. PFAS contamination is a critical challenge due to its widespread presence and persistent nature....


    HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS).
Commenting on the results, Co-Chairman & MD, G V Prasad said: "We achieved double-digit growth across our businesses, driven by successful product launches, increased revenues from key products in the U.S. and the integration of the acquired NRT business. We will continue to strengthen and grow our core businesses through portfolio management and operational excellence, while pursuing strategic partnerships and inorganic growth opportunities.”


Key Business Highlights for Q4FY25



Partnered with Shanghai Henlius Biotech, Inc. to commercialize HLX15 (daratumumab biosimilar) in the U.S. and Europe



Partnered with Bio-Thera Solutions for BAT2206 (ustekinumab biosimilar) for Southeast Asia and Colombia as well as BAT2506 (golimumab biosimilar) for Southeast Asia



Received Biologics License Application (BLA) acceptance for AVT03 (denosumab biosimilar) developed by our partner, Alvotech for the U.S. market



Received ‘Marketing Authorisation’ for rituximab biosimilar from UK MHRA



Participated in India’s ‘Jan Aushadi’ program with one of our products to provide accessible generic medicines to the public



ESG Highlights for Q4FY25



Recognized in the ‘Leadership category’ on the Indian Corporate Governance Scorecard 2024 assessment undertaken by Institutional Investor Advisory Services (IiAS)



Achieved an improved ‘EcoVadis’ score of 73, placing us among the top 15% of companies assessed globally



Won the ‘Climate Action Program 2.0° Award’ in the highest 'Resilient' category in the Light Manufacturing Sector.



Received ‘Excellence in Rural Health Initiative’ award from Economic Times



Other Updates for Q4FY25



Received the Establishment Inspection Report (EIR) following a routine GMP inspection by the U.S. FDA at our API manufacturing facility (CTO-2) in Bollaram, Hyderabad. The inspection was classified as Voluntary Action Initiated (VAI).



Completed the divestment of our manufacturing facility in Shreveport, Louisiana, U.S., to Jaguar Labs Holdings, LLC.



Revenue Analysis



Q4 FY25 consolidated revenues stood at ₹85.1 billion, YoY growth of 20% and QoQ growth of 2%. Excluding the NRT business, underlying growth was 12% YoY and 2% QoQ.

FY25 consolidated revenues reached ₹325.5 billion, YoY growth of 17%. Underlying revenue growth, excluding NRT business was 12% YoY.

The performance was driven by contributions from the acquired NRT business, complemented by steady growth across our core businesses - Global Generics and Pharmaceutical Services & Active Ingredients (PSAI).



Global Generics (GG)



Q4FY25 revenues at ₹75.4 billion, YoY growth of 23% and QoQ growth of 2%. Underlying growth excluding NRT business is 13% YoY and 2% QoQ.

FY25 revenues at ₹289.6 billion, a YoY growth of 18%. Underlying YoY growth excluding NRT business is 13%.

Growth was primarily driven by contributions from the acquired NRT business, higher sales volumes, and new product launches, partially offset by price erosion in North America and Europe.



North America



Q4FY25 revenues at ₹35.6 billion, YoY growth of 9% and QoQ growth of 5%.

FY25 revenues at ₹145.2 billion, YoY growth of 12%.

The YoY growth was primarily driven by new product launches, increased volumes of select key products, partially offset by price erosion in certain products.



During the quarter, we launched seven new products in the U.S. A total of 18 products were launched during the fiscal year.



We filed ten new Abbreviated New Drug Applications (ANDAs) with the USFDA during the fiscal year. As of March 31, 2025, 76 generic filings were pending approval from the USFDA. These comprise of 73 ANDAs and three New Drug Applications (NDAs) filed under Section 505(b)(2) route of the US Federal Food, Drug, and Cosmetic Act. Of the 73 ANDAs, 44 are Paragraph IV applications, and we believe that 20 of these have a ‘First to File’ status.



Europe



Q4FY25 revenues at ₹12.8 billion, YoY growth of 145% and QoQ growth of 5%. This includes revenues from the acquired NRT business. Underlying growth excluding NRT business is 30% YoY and 12% QoQ.


NRT at ₹6.0 billion, QoQ decline of 1%



Germany at ₹3.6 billion, YoY growth of 26% and QoQ growth of 7%



UK at ₹2.2 billion, YoY growth of 43% and QoQ growth of 14%



Rest of Europe at ₹1.1 billion, YoY growth of 20% and QoQ growth of 27%






FY25 revenues at ₹35.9 billion, YoY growth of 75%. Underlying YoY growth excluding NRT business is 16%.


NRT at ₹12.0 billion



Germany at ₹12.9 billion, YoY growth of 21%



UK at ₹7.3 billion, YoY growth of 15%



Rest of Europe at ₹3.7 billion, YoY growth of 4%






The growth in Europe was primarily on account of revenues from the acquired NRT business, momentum in the base business volumes and new product launches, partly offset by price erosion.



During the quarter, we launched 10 new products in the region, taking the full year total to 39.



India



Q4FY25 revenues at ₹13.0 billion, YoY growth of 16% and QoQ decline of 3%.



FY25 revenues at ₹53.7 billion, YoY growth of 16%.

Growth was driven by revenues from the vaccine portfolio in-licensed from Sanofi India, successful new product launches and price increases, partially offset by lower volumes.


As per IQVIA, our IPM rank was maintained at 10. The total no. of new product launches in India is 23 for the full fiscal.



Emerging Markets



Q4FY25 revenues at ₹14.0 billion, YoY growth of 16% and QoQ decline of 3%. YoY growth is largely attributable to new product launches across various countries and higher volumes for existing products. QoQ decline is largely due to lower volumes.

-Revenues from Russia at ₹6.5 billion, YoY growth of 31% and QoQ decline of 7%. YoY growth was largely due to new product launches and higher volumes. QoQ decline was due to lower sales volumes and change in product mix.

-Revenues from other Commonwealth of Independent States (CIS) countries and Romania at ₹2.4 billion, YoY growth of 13% and QoQ growth of 1%. YoY growth was largely on account of higher base business volumes.

-Revenues from Rest of World (RoW) territories at ₹5.0 billion, growth of 1% YoY and QoQ. Contribution from new product launches was partially offset by lower base business volumes and price erosion in certain countries.


FY25 revenues at ₹54.8 billion, YoY growth of 13%. The growth is mainly attributable to higher base business volumes, new launches, partly offset by adverse forex.

-Revenues from Russia at ₹26.0 billion, YoY growth of 16%. The growth was largely on account of improved base business volumes, revenues from new launches and price increases in certain brands.

-Revenues from other CIS countries and Romania at ₹8.9 billion, YoY growth of 3%.

-Revenues from RoW territories at ₹19.9 billion, YoY growth of 12%. The growth is largely due to higher base business volumes and new product launches, partially offset by price erosion.

During Q4FY25, we launched 26 new products across countries, taking the annual total to 85.



Pharmaceutical Services and Active Ingredients (PSAI)



Q4FY25 revenues at ₹9.6 billion, growth of 16% YoY and QoQ.



FY25 revenues at ₹33.8 billion, with a growth of 14% YoY.

Growth was due to increase in API volumes, new launches of API products, partially offset by lower prices. This was further augmented by growth in the pharmaceutical services business.

During the quarter, we filed 52 Drug Master Files (DMFs) globally, taking the annual count to 111.



Income Statement Highlights:


Gross Margin



Q4FY25 at 55.6% (GG: 59.3%, PSAI: 26.3%), a YoY decline of 300 basis points (bps) and a QoQ decline of 312 bps.

YoY decline was attributed to higher price erosion in generics, lower manufacturing overhead leverage and milestone income accrued in the previous year. The sequential decline was mainly due to lower manufacturing overhead leverage and higher milestone income recorded in the previous quarter.

FY25 at 58.5% (GG: 62.0%, PSAI: 27.1%), a YoY decrease of 11 bps, in line with previous year.



Selling, General & Administrative (SG&A) Expenses



Q4FY25 at ₹24.1 billion, YoY increase of 17% and flat QoQ.

FY25 at ₹93.9 billion, YoY increase of 22%.

The increase was largely driven by higher investments in sales and marketing to strengthen existing brands and support new business initiatives, including the expansion of our consumer healthcare portfolio. It also reflects higher personnel costs from our growth initiatives and elevated freight rates.



Research & Development (R&D) Expenses



Q4FY25 at ₹7.3 billion. As % to Revenues – Q4FY25: 8.5% | Q4FY24: 9.7% | Q3FY25: 8.0%.
FY25 at ₹27.4 billion. As % to Revenues – FY25: 8.4% | FY24: 8.2%.

R&D investments continued to support our pipeline across small molecules, biosimilars, complex generics, including peptides, and novel oncology assets.



Impairment on Non-Current Assets



Q4FY25 loss at ₹0.8 billion compared to a reversal of ₹0.2 billion in Q4FY24. The impairment charge relates to certain product-related intangibles from the Mayne portfolio and other assets within our global generics business in India and Europe, impacted by adverse market conditions.

FY25 loss at ₹1.7 billion as compared to ₹0.003 billion in FY24. The impairment of intangibles pertains to product-related assets in India, Europe, and North America, driven by procurement constraints and challenging market conditions.



Net Finance Income/Expense



Q4FY25 income at ₹2.4 billion compared to expense of ₹1.0 billion in Q4FY24.

FY25 income at ₹4.7 billion as compared to ₹4.0 billion in FY24. The increase was largely on account of higher foreign currency exchange gain.



Profit before Tax



Q4FY25 at ₹20.1 billion, a YoY growth of 25% and a QoQ growth of 7%.

As % to Revenues – Q4FY25: 23.6% | Q4FY24: 22.6% | Q3FY25: 22.4%.

FY25 at ₹76.8 billion, a YoY growth of 7%.

As % to Revenues –FY25: 23.6% | FY24: 25.7%.

Profit before tax (‘PBT’) includes ₹888 Mn in Q4 and ₹1,011 Mn in FY25 from the recently acquired NRT business.



Income Tax



Q4FY25 at ₹4.2 billion. As % to PBT – Q4FY25: 20.8% | Q4FY24: 18.4% | Q3FY25: 25.1%.

The effective tax rate (‘ETR’) for the quarter is lower due to:

- Reversal of previously recognized tax provision pertaining to prior years.

- Following the sale of membership interest in one of the group entities, the cumulative foreign exchange gain has been transferred from the foreign currency translation reserve (‘FCTR’) to the income statement. Such FCTR is not subject to taxation.

FY25 at ₹19.5 billion. As % to PBT – FY25: 25.4% | FY24: 22.5%.
The ETR for the full year is higher, primarily due to the reversal of a previously recognized deferred tax asset related to land indexation and recognition of a previously unrecognized deferred tax asset on operating tax losses.



Profit attributable to Equity Holders of Parent Company



Q4FY25 at ₹15.9 billion, a YoY growth of 22% and a QoQ growth of 13%.
As % to Revenues – Q4FY25: 18.7% | Q4FY24: 18.5% | Q3FY25: 16.9%.

FY25 at ₹56.5 billion, a YoY growth of 2%.
As % to Revenues – FY25: 17.4% | FY24: 19.9%.



Diluted Earnings per Share (EPS)



Q4FY25 is ₹19.11. FY25 is ₹67.78.



Other Financial Highlights:


EBITDA



Q4FY25 at ₹24.8 billion, YoY growth of 32% and QoQ growth of 8%.

As % to Revenues – Q4FY25: 29.1% | Q4FY24: 26.4% | Q3FY25: 27.5%.



FY25 at ₹92.1 billion, a YoY growth of 11%.

As % to Revenues – FY25: 28.3% | FY24: 29.7%.



Others:



Operating Working Capital: As on 31st March 2025 at ₹125.9 billion.



Capital Expenditure: Q4FY25 at ₹7.7 billion. FY25 at ₹27.0 billion.



Free Cash Flow: Q4FY25 at ₹11.1 billion. FY25 at ₹13.3 billion.



Net Cash Surplus: As on 31st March 2025 at ₹24.5 billion



Net Debt to Equity: As on 31st March 2025 is (0.07)



Return on Capital Employed (RoCE): FY25 at 27.7%



About key metrics and non-GAAP Financial Measures


This press release contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non-GAAP financial measures are measures of our historical performance, financial position or cash flows that are adjusted to exclude or include amounts from the most directly comparable financial measure calculated and presented in accordance with IFRS.


The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with IFRS. Our non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. These measures may be different from non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes.


We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business.


For more information on our non-GAAP financial measures and a reconciliation of GAAP to non-GAAP measures, please refer to "Reconciliation of GAAP to Non-GAAP Results" table in this press release.


All amounts in millions, except EPS


Reconciliation of GAAP Measures to Non-GAAP Measures


Operating Working Capital


Cash Flow


Net Cash Surplus and Debt to Equity


Computation of RoCE


Computation of Capital Employed:


Computation of EBITDA


Refer page no. 3 & 4.


Earnings Call Details


The management of the Company will host an Earnings call to discuss the Company’s financial performance and answer any questions from the participants.


Date: May 9, 2025


Time: 19:30 pm IST | 10:00 am ET


No password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.


Play Back will be available after the earnings call, till May 16th, 2025. For play back, dial in phone No: +91 22 7194 5757, and playback code is 59320#.


Audio Link and Transcript will be available on the Company’s website: www.drreddys.com


About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil, and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance.


For more information, log on to: www.drreddys.com.


Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2024 and quarterly financial statements filed in Form 6-K with the US SEC for the quarter ended June 30, 2024, September 30, 2024, December 31, 2024 and our other filings with US SEC. The company assumes no obligation to update any information contained herein.

More News From Dr. Reddy’s Laboratories Ltd.

Dr. Reddy’s Q4 & Full Year FY25 Financial Results

<article>
    <div id="bw-release-story" class="press-release ui-kit-press-release-content overflow-hidden bw-release-story ui-kit-press-release-body__story mt-6 lg:mt-10 font-oxygen text-base font-normal leading-[1.5em] lg:text-xl lg:leading-[1.6em]">
        <p xmlns="http://www.w3.org/1999/xhtml"><span>HYDERABAD, India--(<a href="https://www.businesswire.com" target="_blank">BUSINESS WIRE</a>)--</span>Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS).</p>
        <div class="w-full text-sm leading-[21px] lg:text-base lg:leading-6 table-container ui-kit-table-container mb-8 font-helvetica">
            <div class="bw-release-table ui-kit-release-table w-full clusterize-scroll" id="ui-kit-table-container-1">
                <table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100">
                    <tbody>
                        <tr>
                            <td class="bwvertalignb bwpadl0 bwwidth37" rowspan="1" colspan="1"></td>
                            <td class="bwvertalignb bwpadl0 bwwidth1" rowspan="1" colspan="1"></td>
                            <td class="bwvertalignb bwpadl0 bwalignc bwrightsingle bwwidth37" rowspan="1" colspan="1">
                                <p class="bwalignc bwcellpmargin"><b>Q4FY25</b></p>
                            </td>
                            <td class="bwwidth1" rowspan="1" colspan="1"></td>
                            <td class="bwvertalignb bwpadl0 bwalignc bwwidth24" rowspan="1" colspan="1">
                                <p class="bwalignc bwcellpmargin"><b>FY25</b></p>
                            </td>
                        </tr>
                        <tr>
                            <td class="bwpadl0 bwwidth37" rowspan="1" colspan="1"></td>
                            <td class="bwpadl0 bwwidth1" rowspan="1" colspan="1"></td>
                            <td class="bwpadl0 bwrightsingle bwwidth37" rowspan="1" colspan="1"></td>
                            <td class="bwpadl0 bwwidth1" rowspan="1" colspan="1"></td>
                            <td class="bwpadl0 bwwidth24" rowspan="1" colspan="1">&nbsp;</td>
                        </tr>
                        <tr>
                            <td class="bwpadl0 bwvertalignt bwwidth37" rowspan="1" colspan="1"><b>Revenues</b></td>
                            <td class="bwvertalignb bwpadl0 bwwidth1" rowspan="1" colspan="1"></td>
                            <td class="bwvertalignb bwpadl0 bwrightsingle bwnowrap bwwidth37 bwalignl" rowspan="1" colspan="1">
                                <p class="bwalignl bwcellpmargin"><b>₹ 85,060 Mn</b></p>
                            </td>
                            <td class="bwwidth1" rowspan="1" colspan="1"></td>
                            <td class="bwvertalignb bwpadl0 bwwidth24 bwalignl" rowspan="1" colspan="1">
                                <p class="bwalignl bwcellpmargin"><b>₹ 325,535 Mn</b></p>
                            </td>
                        </tr>
                        <tr>
                            <td class="bwpadl0 bwvertalignt bwwidth37" rowspan="1" colspan="1"></td>
                            <td class="bwvertalignb bwpadl0 bwwidth1" rowspan="1" colspan="1"></td>
                            <td class="bwtablemarginb bwblockalignl bwrightsingle bwnowrap bwwidth37 bwalignl" rowspan="1" colspan="1">
                                <p class="bwalignl bwcellpmargin">[Up: 20% YoY^; 2% QoQ]</p>
                            </td>
                            <td class="bwwidth1" rowspan="1" colspan="1"></td>
                            <td class="bwnowrap bwwidth24 bwalignl" rowspan="1" colspan="1">
                                <p class="bwalignl bwcellpmargin">[Up: 17% YoY^]</p>
                            </td>
                        </tr>
                        
                        <tr>
                            <td class="bwpadl0 bwwidth37" rowspan="1" colspan="1"><b>Profit for the Period</b></td>
                            <td class="bwvertalignb bwpadl0 bwwidth1" rowspan="1" colspan="1"></td>
                            <td class="bwvertalignb bwpadl0 bwwidth37 bwalignl" rowspan="1" colspan="1"><p class="bwalignl bwcellpmargin"><b>₹ 15,939 Mn</b></p></td>
                            <td class="bwwidth1" rowspan="1" colspan="1"></td>
                            <td class="bwvertalignb bwpadl0 bwwidth24 bwalignl" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"><b>₹ 56,544 Mn</b></p></td>
                        </tr>
                        <tr>
                            <td class="bwwidth37 bwalignl" rowspan="1" colspan="1">
                                <p class="bwalignl bwcellpmargin"><b>attributable to Equity Holders</b></p>
                            </td>
                            <td class="bwvertalignb bwpadl0 bwwidth1" rowspan="1" colspan="1"></td>
                            <td class="bwrightsingle bwnowrap bwwidth37 bwalignl" rowspan="1" colspan="1">
                                <p class="bwalignl bwcellpmargin">[Up: 22% YoY; 13% QoQ]</p>
                            </td>
                            <td class="bwwidth1" rowspan="1" colspan="1"></td>
                            <td class="bwvertalignb bwpadl0 bwnowrap bwwidth24 bwalignl" rowspan="1" colspan="1">
                                <p class="bwcellpmargin bwalignl">[Up: 2% YoY]</p>
                            </td>
                        </tr>
                    </tbody>
                </table>
                <button type="button" class="expand-button absolute top-4 right-4 flex items-center text-primaryMed">
                    <svg width="26" height="26" fill="none" xmlns="http://www.w3.org/2000/svg">
                        <path d="M21.9375 16.25V21.9375H16.25M21.4195 21.418L15.4375 15.4375M4.0625 9.75V4.0625H9.75M4.58047 4.58199L10.5625 10.5625M16.25 4.0625H21.9375V9.75M21.418 4.58047L15.4375 10.5625M9.75 21.9375H4.0625V16.25M4.58199 21.4195L10.5625 15.4375" stroke="currentColor"></path>
                    </svg>
                    <span class="text-sm ml-4 font-bold">Expand</span>
                </button>
            </div>
        </div>
        <p xmlns="http://www.w3.org/1999/xhtml">
            <b><i>Commenting on the results, Co-Chairman &amp; MD, G V Prasad said:</i></b><i> "We achieved double-digit growth across our businesses, driven by successful product launches, increased revenues from key products in the U.S. and the integration of the acquired NRT business. We will continue to strengthen and grow our core businesses through portfolio management and operational excellence, while pursuing strategic partnerships and inorganic growth opportunities.”</i>
        </p>
        <div class="w-full text-sm leading-[21px] lg:text-base lg:leading-6 table-container ui-kit-table-container mb-8 font-helvetica">
            <div class="bw-release-table ui-kit-release-table w-full clusterize-scroll" id="ui-kit-table-container-2">
                <table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100">
                    <tbody>
                        <tr>
                            <td colspan="2" class="bwpadl0" rowspan="1"><i>All amounts in millions, except EPS</i></td>
                        </tr>
                        <tr>
                            <td colspan="2" class="bwpadl0" rowspan="1">
                                <p class="bwcellpmargin">
                                    <i>All US dollar amounts based on convenience translation rate of 1 USD = </i>₹<i>85.43</i>
                                </p>
                            </td>
                        </tr>
                    </tbody>
                </table>
                <button type="button" class="expand-button absolute top-4 right-4 flex items-center text-primaryMed">
                    <svg width="26" height="26" fill="none" xmlns="http://www.w3.org/2000/svg">
                        <path d="M21.9375 16.25V21.9375H16.25M21.4195 21.418L15.4375 15.4375M4.0625 9.75V4.0625H9.75M4.58047 4.58199L10.5625 10.5625M16.25 4.0625H21.9375V9.75M21.418 4.58047L15.4375 10.5625M9.75 21.9375H4.0625V16.25M4.58199 21.4195L10.5625 15.4375" stroke="currentColor"></path>
                    </svg>
                    <span class="text-sm ml-4 font-bold">Expand</span>
                </button>
            </div>
        </div>
        
    </div>
</article>

Dr. Reddy's reported ₹85.1 billion in revenues, with a 20% YoY growth.
Successful product launches contributed to double-digit growth in multiple markets.
Partnerships in biosimilars expected to enhance market presence in the U.S. and Europe.
Gross margins declined due to pricing pressure in generics and rising costs.
RSY's successful year highlights potential for sustainable future growth.

News insight

Dr. Reddy’s Q4 & Full Year FY25 Financial Results

AI summary

Sentiment rationale

Key facts

Corporate Developments